Investigating how a specific modification of the androgen receptor affects spinal and bulbar muscular atrophy.
Official title: The mechanism and role of androgen receptor Serine 16 phosphorylation in SBMA
Funded at Thomas Jefferson University · NIH-10952790 · Data updated 2026-11-12
This study is looking at how a specific change in a protein related to hormones affects nerve cell health in people with spinal and bulbar muscular atrophy (SBMA), with the hope of finding new ways to help treat the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $429,000 |
| NIH project number | 1R21NS139090-01 |
| Project ID | NIH-10952790 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with spinal and bulbar muscular atrophy or related neurodegenerative conditions.
✕Less likely to help
Patients with neurodegenerative diseases not related to androgen receptor dysfunction may not benefit from this research.
What this research studies
This research focuses on understanding the role of a specific modification (Serine 16 phosphorylation) of the androgen receptor in spinal and bulbar muscular atrophy (SBMA), a neuromuscular disease. By using advanced cell and mouse models, the study aims to uncover the mechanisms that lead to neuronal dysfunction and death in SBMA. The researchers will explore how hormone binding influences the toxicity of the androgen receptor, which is crucial for developing potential therapies. Patients may benefit from insights gained into the disease process and the development of targeted treatments.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating spinal and bulbar muscular atrophy and related neurodegenerative diseases.
How similar studies have gone: Previous research has shown promising results in understanding the mechanisms of other polyglutamine diseases, suggesting potential for success in this area as well.
Where this research is happening
-
Thomas Jefferson University
Philadelphia, United States Active
Researchers
- Principal investigator: Merry, Diane E — Thomas Jefferson University
- Study coordinator: Merry, Diane E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.